Welcome to our dedicated page for Whitehawk Therapeutics news (Ticker: WHWK), a resource for investors and traders seeking the latest updates and insights on Whitehawk Therapeutics stock.
Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) is a clinical-stage oncology therapeutics company developing antibody-drug conjugate (ADC) cancer treatments, and its news flow reflects this focus on targeted oncology and biomarker-driven research. Company updates highlight progress across an advanced three-asset ADC portfolio targeting clinically validated proteins PTK7, MUC16 and SEZ6 in solid tumors.
Investors and observers following WHWK news will see announcements on key clinical and regulatory milestones, such as clearance of the Investigational New Drug (IND) application for the PTK7-targeted ADC HWK-007 and the submission of an IND for the MUC16-targeted ADC HWK-016. News also covers the start and design of Phase 1, multicenter, open-label trials in adults with advanced or metastatic solid tumors that are refractory to standard therapies, including initial evaluation in lung, ovarian and endometrial cancers for HWK-007 and high MUC16-expressing gynecologic cancers for HWK-016.
Whitehawk’s releases further include scientific updates, such as presentation of a real-world analysis confirming PTK7 as a broadly expressed, clinically relevant target across solid tumors at the AACR-NCI-EORTC conference, and collaboration announcements like its multi-year agreement with Tempus AI to support biomarker-driven oncology research. Corporate news items feature financial results, participation in healthcare and biotechnology investor conferences, and senior leadership appointments related to clinical development.
This WHWK news page aggregates these types of developments so readers can review regulatory updates, clinical trial progress, scientific presentations, collaborations and financial disclosures in one place. For those tracking ADC-focused oncology companies, it provides a centralized view of Whitehawk Therapeutics’ reported activities and milestones over time.
Whitehawk Therapeutics (Nasdaq: WHWK) will present three preclinical abstracts at the AACR Annual Meeting 2026 in San Diego, April 17–22, 2026. Presentations cover ADC programs HWK-016 (oral minisymposium), HWK-007 (poster) and HWK-206 (poster).
Preclinical highlights include tumor regressions at low single-digit mg/kg doses, a highest non-severely toxic dose (HNSTD) of 60 mg/kg in non-human primates, and low circulating free payload tied to a proprietary carbon-bridge cysteine repairing linker-payload.
Whitehawk Therapeutics (Nasdaq: WHWK) reported Q4 and full-year 2025 results and development updates on March 12, 2026. Key points: $145.7M cash and short-term investments at year-end, active Phase 1 recruitment for HWK-007 and HWK-016, and a planned IND submission for HWK-206 in mid-2026 with Phase 1 start targeted for Q3 2026.
Full-year net loss was $20.6M (includes an $87.3M gain from the AADI divestiture); Q4 net loss was $23.3M. Preclinical data presentation expected spring 2026; initial Phase 1 results expected in 1H 2027.
Whitehawk Therapeutics (Nasdaq: WHWK) will participate in three investor conferences in early March 2026: TD Cowen, Leerink Global Healthcare, and Citizens Life Sciences. Presentations and investor meetings feature CEO Dave Lennon and other executives.
TD Cowen presentation and fireside chat: March 3, 10:30 AM ET. Leerink investor meetings: March 9. Citizens corporate presentation: March 10, 12:30 PM ET. A live webcast of TD Cowen and Citizens presentations will be available on the company's investor relations website and replayed for ~30 days.
Whitehawk Therapeutics (Nasdaq: WHWK) announced that Dave Lennon, PhD, President and CEO, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 at 8:40 AM ET. The company is a clinical-stage oncology therapeutics firm focused on antibody drug conjugates (ADC).
A live webcast will be available via the company's investor relations website and will be replayable for approximately 30 days after the presentation.
Whitehawk Therapeutics (Nasdaq: WHWK) announced FDA clearance of the IND for HWK-007, a PTK7-targeted ADC, and disclosed an IND submission in December 2025 for HWK-016, a MUC16-targeted ADC. HWK-007 Phase 1 is actively recruiting and will initially evaluate lung, ovarian and endometrial cancers; HWK-016 Phase 1 is anticipated to begin recruiting this quarter and will initially target ovarian and endometrial cancers. Both programs use Whitehawk's ADC platform with a cleavable linker and a TOP1 inhibitor payload. The company expects initial clinical data from both trials in early 2027.
Whitehawk Therapeutics (Nasdaq: WHWK) announced on December 1, 2025 the appointment of Margaret Dugan, MD, as Chief Medical Officer.
Dr. Dugan brings more than 30 years of global oncology drug development experience, leadership in early-stage development, oversight of more than 12 Phase 1 programs, and involvement in regulatory approvals for multiple oncology drugs. She previously led early development at Novartis, served as CMO at Dracen Pharmaceuticals and Schrödinger, and advanced programs from proof-of-concept into clinical stages, including delivering three Phase 1 assets and moving a program to Phase 2 readiness in under 18 months. Whitehawk said the hire supports its plan to advance ADC programs toward clinical development.
Whitehawk Therapeutics (Nasdaq: WHWK) announced that Dave Lennon, PhD, President and CEO, will participate in a fireside discussion at the Piper Sandler 37th Annual Healthcare Conference in New York City on December 3, 2025 at 12:30 PM ET. A live webcast will be available on the company's investor relations website and will be replayable for approximately 30 days after the event.
Whitehawk Therapeutics (Nasdaq: WHWK) announced that Dave Lennon, PhD, President and CEO, will present at the Jefferies Global Healthcare Conference in London on November 18, 2025 at 11:30 AM GMT.
A live webcast of the presentation will be available via the company's investor relations website and will be available for replay for approximately 30 days following the event.
Whitehawk Therapeutics (Nasdaq: WHWK) reported Q3 2025 results and operational progress on Nov 6, 2025. Cash, cash equivalents and short-term investments were $162.6M as of Sept 30, 2025 versus $47.2M on Dec 31, 2024. The company reported a net loss of $17.7M for Q3 2025 vs. $12.5M for Q3 2024.
Whitehawk reaffirmed planned IND submissions for HWK-007 and HWK-016 by year-end 2025 and an IND for HWK-206 by mid-2026, stated runway into 2028, and presented PTK7 expression data at AACR-NCI-EORTC.
Whitehawk Therapeutics (Nasdaq: WHWK) presented a large real-world RNA analysis of PTK7 at AACR‑NCI‑EORTC on Oct 24, 2025. The study evaluated >157,000 tumor samples and found PTK7 expressed in ~70% of solid tumors, ranking PTK7 as the third most highly expressed ADC target after HER2 and HER3. Highest median PTK7 mRNA levels were reported in endometrial (7.4), ovarian (7.2), head and neck (7.1), NSCLC (6.9) and breast (6.7).
Expression was stable across histologic subtypes, disease stage and metastatic status. Whitehawk plans an IND filing for HWK‑007 (a PTK7‑directed ADC with a TOPO1 payload) by year‑end, targeting initial trials in NSCLC, ovarian and endometrial cancers.